New combo therapy targets deadly brain cancer in early trial
Disease control
Recruiting now
This early-stage study tests whether two experimental drugs, ABBV-637 and ABBV-155, are safe when given alone or with another drug called ERAS-801 for people whose glioblastoma has come back. About 60 adults with a specific type of brain tumor (EGFR gene amplified) will take part…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Apr 26, 2026 19:38 UTC